Triangulate Health Ltd

Providing insight and analysis in the interface between economics, science and policy.

[Triangulate Health Ltd @triangulate_ltd]

Access to safe, effective, quality and affordable medicines is 🔑 to achieving #UHC

Join us at 14:00 CET for our last #OsloMedicinesInitiative webinar on the roles and responsibilities of the public sector and private sector in improving #access2meds

👉https://t.co/tGIHepVydn

[WHO/Europe @WHO_Europe]

In the WHO European Region, 6⃣ to 1⃣0⃣ out of every 100 people live with a disability. In total, an estimated 135 million people in Europe live with a disability

Find out more at #EDS2022 tomorrow 👉https://t.co/WzDlQjOqCx

[Allison Colbert @AllisonMColbert]

All of this. When treatments are found to be truly effective they must be made rapidly available to both health systems and the individuals who need them at an affordable price.

[Triangulate Health Ltd @triangulate_ltd]

Join Dr Christina Pallitto @WHO and David Tordrup @triangulate_ltd on Thursday 3 February at 14:00 CET to discuss the investment case to end female genital mutilation.

Invest to #EndFGM

Register 👉https://t.co/86R2FB2Cze

[WHO African Region @WHOAFRO]

Female Genital Mutilation is a violation of human rights! 🚫

✅ Join in this Thursday! @WHO @triangulate_ltd & partners will discuss the economic burden of #FGM in high-prevalence countries. Register now ➡️ https://t.co/HI5eHfg491

⏰ 14:00-15:30 (GMT+1)
🗓️ Thursday 3 February

[David Tordrup @dtordrup]

Join @WHO and @Triangulate_ltd on 3rd February at 14:00 CET to discuss the economic burden of #FGM and actions countries can implement to achieve SDG Target 5.3 to eliminate all harmful practices such as FGM. Register here: https://t.co/jtFCzC0ekc Invest to #EndFGM

[Prof. Dame Sally Davies @UKAMREnvoy]

New data showing the global burden of AMR is a wake up call to make progress on AMR.

Read my article on the global need for multilateral action, public engagement, and private sector leadership ⤵️
https://t.co/nJlzkUc3rb

[Triangulate Health Ltd @triangulate_ltd]

What pricing, reimbursement and coverage policies are needed to ensure sustainable access to affordable innovative medicines? 💊💉

Learn from experts from across the WHO European Region 🌍#OsloMedicinesInitiative

Join us today🕑 14:00 CET
👉https://t.co/jzNYWb9p0z

[Triangulate Health Ltd @triangulate_ltd]

Tune in 📽️at 14:00 CET today for the 2nd webinar under the #OsloMedicinesInitiative, discussing w/experts and practitioners how we can support policy-makers to more effectively finance novel medicines.

Triangulate's @dtordrup is delighted to contribute on the panel 🙏

[The Lancet @TheLancet]

NEW—An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections, more deaths than HIV/AIDS or malaria.

#GRAMPaper reveals the scale of antimicrobial resistance (#AMR), now a leading cause of death worldwide: https://t.co/2h5UEKemEq #AMRSOS

[John-Arne Røttingen @jarottingen]

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Important study that estimates that lack of effectiveness of antibiotics causes more deaths than malaria and hiv https://t.co/OSWXv4cz5a

[Manica Balasegaram @Manica_amr]

Antimicrobial resistance now a leading cause of death worldwide, study finds - very worrying data that requires urgent action. https://t.co/SvmTxLkNz0

[Triangulate Health Ltd @triangulate_ltd]

How can we modify the current pharmaceutical R&D system to ensure that the right medicines are available at the right price?

Learn from innovative approaches to financing of R&D applied in niche sectors to date in the🇺🇳European Region.

Join us tomorrow 👉https://t.co/I8S1JlUFIe

[The European Public Health Alliance (EPHA) @EPHA_EU]

Skyrocketing prices of🆕medicines are a burden for patients across Europe. Can they be justified by allegedly high R&D costs? How to calculate a fair price? What are the 🇪🇺 plans to improve #affordability?💊
Join our webinar TOMORROW 👇https://t.co/vm3gEJFGL7
#AccesstoMedicines

[Bente Mikkelsen @MikkelsenBente_]

🍃🌍: Yet another example of the need to integrate the NCD and climate agendas together: congratulations to all authors on their timely report. https://t.co/y3rg29Q8tA

[Rebekka Aarsand @rebekkagrant]

Thanks for very fruitful meetings yesterday and for your leadership @hans_kluge, @helse_og_omsorg & @Legemiddelinfo 🇳🇴 So proud to be part of this important work in making effective, novel, high cost medicines more accessible to patients🙏#OsloMedicinesInitiative

[Geneva Association @TheGenevaAssoc]

In this month's @AIReDaily Adrita Bhattacharya-Craven and @dtordrup & @rebekkagrant (@triangulate_ltd) outline the risks #AntimicrobialResistance poses to insurers, plus steps they can take to raise awareness of this potential public health crisis.

https://t.co/g3AfDqEzic

[WHO/Europe @WHO_Europe]

Our #OsloMedicinesInitiative is here to promote fair + equitable access to high-priced, novel medicines.

Our new series of webinars is kicking off on 13 January. See here for topics and registration links 👉 https://t.co/FX8SOqc62a

[Int. Centre for Antimicrobial Resistance Solutions @ICARS_global]

"At what point will insurers & health providers have to reconsider the risk of replacing an arthritic joint due to the risk of an untreatable infection?"

Interesting #MondayRead on #AMR & the risk-benefit balance ⬇️@rebekkagrant @dtordrup @TheGenevaAssoc https://t.co/sjsryKJ4y0

[Sophie Rose @SophieMRose_]

What features of countries’ are associated with the quality of their COVID-19 response? 🌎

Read our new @GlobalHealthBMJ piece “Analysing COVID-19 outcomes in the context of the 2019 Global Health Security (GHS) Index” to learn more: https://t.co/D60EAXXKlH

A summary 🧵— 1/

[AMR Action Fund @AMRActionFund]

"You’ve got a broken business model.” ICYMI, our Board Chair Bill Burns was featured in this recent @FT article on the “growing international momentum” toward pull incentives to spur and sustain antibiotic R&D https://t.co/13reGOTvm7 #AMR